PRISM BioLab Co.,LTD
JPX: 206A.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dai Takehara
- Employees
- 27
- Headquarters
- Fujisawa, Japan
- IPO year
- 2024
- Market cap
- ¥6.5B
- Website
- http://www.prismbiolab.com
Loading 206A…
Loading profile data…Frequently asked questions about 206A
What does PRISM BioLab Co.,LTD (206A.T) do?
PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-...
Where does 206A.T trade?
PRISM BioLab Co.,LTD (206A.T) trades on the Tokyo Stock Exchange.
What sector is 206A.T in?
PRISM BioLab Co.,LTD (206A.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PRISM BioLab Co.,LTD?
Dai Takehara is the chief executive officer of PRISM BioLab Co.,LTD (206A.T).
Where is PRISM BioLab Co.,LTD headquartered?
PRISM BioLab Co.,LTD is headquartered in Japan.
Does 206A.T pay a dividend?
PRISM BioLab Co.,LTD (206A.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 206A.T go public?
PRISM BioLab Co.,LTD (206A.T) completed its initial public offering in 2024.